Associated Papers
Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies.
Ojala VK et al.
Molecular Oncology, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
41152984 (PubMed )
Supplement: 13073_2025_1564_MOESM2_ESM.xlsx › Table_S6
An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations.
Chakroborty D et al.
Cancer Research Communications, 2022
Select a paper to view details